These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30121642)

  • 41. BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy.
    Akashi-Tanaka S; Watanabe C; Takamaru T; Kuwayama T; Ikeda M; Ohyama H; Mori M; Yoshida R; Hashimoto R; Terumasa S; Enokido K; Hirota Y; Okuyama H; Nakamura S
    Clin Breast Cancer; 2015 Feb; 15(1):80-5. PubMed ID: 25445419
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of weekly paclitaxel plus carboplatin followed by anthracycline chemotherapy on the neoadjuvant treatment of patients with triple-negative breast cancer.
    Castrellon AB; Velez M; Nguyen SM; Blaya M; Barnick S; Dumais K; LeCroy N; Raez LE
    Hematol Oncol Stem Cell Ther; 2018 Mar; 11(1):30-33. PubMed ID: 29100977
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort.
    Sella T; Gal Yam EN; Levanon K; Rotenberg TS; Gadot M; Kuchuk I; Molho RB; Itai A; Modiano TM; Gold R; Kaufman B; Shimon SP
    Breast; 2018 Aug; 40():141-146. PubMed ID: 29800932
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predictive Clinicopathologic and Dynamic Contrast-Enhanced MRI Findings for Tumor Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Eom HJ; Cha JH; Choi WJ; Chae EY; Shin HJ; Kim HH
    AJR Am J Roentgenol; 2017 Jun; 208(6):W225-W230. PubMed ID: 28350486
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment response as predictor for brain metastasis in triple negative breast cancer: A score-based model.
    Gabani P; Weiner AA; Hernandez-Aya LF; Khwaja S; Roach MC; Ochoa LL; Mullen D; Thomas MA; Matesa MA; Margenthaler JA; Cyr AE; Naughton MJ; Ma C; Sanati S; Zoberi I
    Breast J; 2019 May; 25(3):363-372. PubMed ID: 30920124
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gene signature-based prediction of triple-negative breast cancer patient response to Neoadjuvant chemotherapy.
    Zhao Y; Schaafsma E; Cheng C
    Cancer Med; 2020 Sep; 9(17):6281-6295. PubMed ID: 32692484
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Analysis of the factors influencing adjuvant chemotherapy decisions for triple negative breast cancer].
    Hong J; Chen XS; Wu JY; Huang O; Zhu L; He JR; Fang Q; Chen WG; Li YF; Shen KW
    Zhonghua Zhong Liu Za Zhi; 2017 Jan; 39(1):39-43. PubMed ID: 28104032
    [No Abstract]   [Full Text] [Related]  

  • 48. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.
    Ács B; Zámbó V; Vízkeleti L; Szász AM; Madaras L; Szentmártoni G; Tőkés T; Molnár BÁ; Molnár IA; Vári-Kakas S; Kulka J; Tőkés AM
    Diagn Pathol; 2017 Feb; 12(1):20. PubMed ID: 28222768
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy.
    Wu K; Yang Q; Liu Y; Wu A; Yang Z
    World J Surg Oncol; 2014 Apr; 12():95. PubMed ID: 24731479
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gene expression alterations predict the pathological complete response in triple-negative breast cancer exploratory analysis of the NACATRINE trial.
    Freitas AJA; Nunes CR; Mano MS; Causin RL; Santana IVV; de Oliveira MA; Calfa S; Silveira HCS; de Pádua Souza C; Marques MMC
    Sci Rep; 2023 Dec; 13(1):21411. PubMed ID: 38049525
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Melanoma long non-coding RNA signature predicts prognostic survival and directs clinical risk-specific treatments.
    Chen X; Guo W; Xu XJ; Su F; Wang Y; Zhang Y; Wang Q; Zhu L
    J Dermatol Sci; 2017 Mar; 85(3):226-234. PubMed ID: 27955882
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Humbert O; Riedinger JM; Charon-Barra C; Berriolo-Riedinger A; Desmoulins I; Lorgis V; Kanoun S; Coutant C; Fumoleau P; Cochet A; Brunotte F
    Clin Cancer Res; 2015 Dec; 21(24):5460-8. PubMed ID: 26130460
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Circulating lncRNA H19 may be a useful marker of response to neoadjuvant chemotherapy in breast cancer.
    Özgür E; Ferhatoğlu F; Şen F; Saip P; Gezer U
    Cancer Biomark; 2020; 27(1):11-17. PubMed ID: 31640083
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Knockdown of lncRNA H19 restores chemo-sensitivity in paclitaxel-resistant triple-negative breast cancer through triggering apoptosis and regulating Akt signaling pathway.
    Han J; Han B; Wu X; Hao J; Dong X; Shen Q; Pang H
    Toxicol Appl Pharmacol; 2018 Nov; 359():55-61. PubMed ID: 30244121
    [TBL] [Abstract][Full Text] [Related]  

  • 55. LncRNA BCAR4 expression predicts the clinical response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
    Gan FJ; Li Y; Xu MX; Zhou T; Wu S; Hu K; Li Y; Sun SH; Luo Q
    Cancer Biomark; 2021; 32(3):339-351. PubMed ID: 34151842
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients.
    Oda N; Shimazu K; Naoi Y; Morimoto K; Shimomura A; Shimoda M; Kagara N; Maruyama N; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2012 Nov; 136(1):107-16. PubMed ID: 22986814
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.
    Clavarezza M; Turazza M; Aitini E; Saracchini S; Garrone O; Durando A; De Placido S; Bisagni G; Levaggi A; Bighin C; Restuccia E; Scalamogna R; Galli A; Del Mastro L
    Breast; 2013 Aug; 22(4):470-5. PubMed ID: 23642526
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes.
    Lee HJ; Lee JJ; Song IH; Park IA; Kang J; Yu JH; Ahn JH; Gong G
    Breast Cancer Res Treat; 2015 Jun; 151(3):619-27. PubMed ID: 26006068
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial.
    Futamura M; Nagao Y; Ishihara K; Takeuchi M; Nakada T; Kawaguchi Y; Asano M; Kumazawa I; Shiroko T; Morimitsu K; Mori R; Nawa M; Shimokawa T; Yoshida K
    Breast Cancer; 2017 Jul; 24(4):615-623. PubMed ID: 28050738
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Features from Computerized Texture Analysis of Breast Cancers at Pretreatment MR Imaging Are Associated with Response to Neoadjuvant Chemotherapy.
    Chamming's F; Ueno Y; Ferré R; Kao E; Jannot AS; Chong J; Omeroglu A; Mesurolle B; Reinhold C; Gallix B
    Radiology; 2018 Feb; 286(2):412-420. PubMed ID: 28980886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.